Archive for the ‘Gene Therapy Research’ Category

Cytori Therapeutics, Inc. ( CYTX ) provided preliminary data from a study evaluating a potential treatment for scleroderma based on the company's cell therapy. The investigator-funded, open-label, pilot study is being conducted on patients with cutaneous systemic scleroderma in France.

12 patients were administered Cytori's cell therapy, injected into their fingers. Safety and hand function improvement are the primary endpoints of the study which were measured by the Cochin hand functional scale at six months.

At the end of the two month follow-up period, no infection, ischemic complications or serious adverse events were observed. Moreover, there was a significant improvement in the Cochin hand function disability scale.

As far as secondary endpoints are concerned, there was a significant improvement in scleroderma health assessment questionnaire score and in Raynaud's Severity Score. Also, there was a significant improvement in hand pain when measured by the visual analog pain scale.

Cytori is focused primarily on the development of treatments for cardiovascular disease and soft tissue injuries and burns based on its proprietary cell therapy formulation. The company's cell therapy is based on the formulation of stem and regenerative cells derived from a patient's own adipose (fat) tissue (ADRCs). The company has also designed the Celution System, a tissue processing system, to access the cells from a patient during the surgery procedure.

We note that last month Cytori's Celution System gained approval from the Australian regulatory body for commercial use for autologous re-implantation or re-infusion of a patient's ADRCs.

The company is currently conducting Athena, a multi-center, double-blind, randomized and placebo-controlled study for evaluating its cell therapy in 45 patients with chronic ischemic heart failure. The company expects to complete patient enrollment in the fourth quarter of this year. 6-month top-line data from the study is expected in the first half of next year.

Cytori carries a Zacks Rank #4 (Sell). Companies that currently look well-positioned include Gilead Sciences Inc. ( GILD ) and Actelion Ltd. ( ALIOF ) with a Zacks Rank #1 (Strong Buy), and Jazz Pharmaceuticals ( JAZZ ) with a Zacks Rank #2 (Buy).

ACTELION LTD (ALIOF): Get Free Report

CYTORI THERAPEU (CYTX): Free Stock Analysis Report

Originally posted here:
Data on Cytori's Cell Therapy - Analyst Blog

Public release date: 22-Sep-2013 [ | E-mail | Share ]

Contact: Rachel Steinhardt rsteinhardt@licr.org 212-450-1582 Ludwig Institute for Cancer Research

New York, NY and Stockholm, Sweden -- A team of researchers affiliated with Ludwig Cancer Research and the Karolinska Institutet in Sweden report in the current issue of Nature Methods a dramatically improved technique for analyzing the genes expressed within a single cell -- a capability of relevance to everything from basic research to future cancer diagnostics.

"There are cells in tumors and in healthy tissues that are not present in sufficient numbers to permit analysis using anything but single-cell methods," explains senior author, Rickard Sandberg, PhD. "This method allows us to identify rare and important subpopulations of cells in all sorts of tissues. We can also use it to tease apart, more rigorously than ever before, how the expression of unique suites of genes transform cells from one state to another as, say, an embryo develops into an organism, or a tumor becomes metastatic."

Traditional approaches, which depend on the collective analysis of gene expression in millions of cells at once, tend to obscure biologically significant differences in the genes expressed by specialized cells within a particular kind of tissue. Single-cell analysis of gene expression overcomes this limitation. The leading method for such analysis -- Smart-seq -- was developed in 2012 by the biotechnology firm Illumina, together with Sandberg's laboratory.

To develop the new technique, named Smart-seq2, Sandberg's team conducted more than 450 experiments to improve upon their initial method. The new procedure consistently captures three to four times as many RNA molecules, which often translates into 2,000 more genes per cell than current methods allow. It also captures far more full-length gene sequences, a steep challenge in such studies, which often capture only partial sequences of expressed genes. This will permit researchers to conduct a more granular analysis of how subtle differences between the same genes in different people -- known as single nucleotide polymorphisms (or SNPs) -- contribute to differences in biology and disease.

The new method is likely to be of great value to cancer research. Identifying rare sub-populations of cells in tumors and understanding their role in the survival and progression of cancers can provide invaluable information for the development of diagnostics and targeted therapies. A study recently published by Ludwig researchers described, for example, how certain subpopulations of cells in melanomas can be pushed into a drug-susceptible state and then destroyed by chemotherapy. More such strategies might be devised as researchers get a better handle on the cellular species found in different types of tumors, and the patterns of gene expression that define them.

Because Smart-seq2 relies on off-the-shelf reagents, it costs roughly a twentieth as much as the commercialized kit, which should allow researchers to conduct sophisticated analyses of single cells on a much larger scale. It can also be improved further by the scientific community, since its constituent components and rationale are both open to the public.

Armed with the more effective and affordable Smart-seq2, Sandberg's lab is now moving ahead on projects that require a large-scale, single-cell gene expression analysis. "Now all researchers can do their own single-cell gene expression analysis by buying the components of the process described in this paper and assembling their own kits," says Sandberg.

###

Read the original:
A boost for cellular profiling

Neurologists believe they have come a step closer to being able to erase unshakable haunting memories.

In research sounding like the plot of a sci-fi film, a group of researchers believe they have found the gene which performs the role of memory extinction.

The process, which occurs when new memories overwrite old ones, is being treated as the key to eventually being able completely to delete painful memories.

The research could lead to medical advances and the successful treatment of those suffering from Post Traumatic Stress Disorder or sufferers tormented by earlier experiences.

Scientists at Massachusetts Institute of Technology in America conducted the study.

They say that if a way can be found to amplify the activity of the gene, known as Tet1, it could change lives.

The research echoes the 2004 Jim Carrey and Kate Winslet film, Eternal Sunshine Of The Spotless Mind in which memories are wiped.

As part of their study, the researchers compared learning behaviour of mice with the Tet1 to mice who had their version of the gene inhibited, or as the scientists put it, "knocked out".

Both sets were trained to fear a certain cage by giving them a mild electric shock each time they were placed inside.

Link:
A Cure For Post Traumatic Stress Disorder? New Treatment Could Erase Haunting Memories

In research sounding like the plot of a sci-fi film, neurologists believe they have come a step closer to being able to erase haunting memories.

A group of US researchers believe they have found the gene which performs the role of memory extinction.

The process, which occurs when new memories overwrite old ones, is being treated as the key to eventually being able completely to delete painful memories.

The research could lead to medical advances and the successful treatment of those suffering from post-traumatic stress disorder or sufferers tormented by earlier experiences.

Scientists at Massachusetts Institute of Technology who conducted the study say that if a way can be found to amplify the activity of the gene, known as Tet1, it could change lives.

The research echoes the 2004 Jim Carrey and Kate Winslet film, Eternal Sunshine Of The Spotless Mind in which memories are wiped.

As part of their study, the researchers compared learning behaviour of mice with the Tet1 to mice who had their version of the gene inhibited, or as the scientists put it, "knocked out".

Both sets were trained to fear a certain cage by giving them a mild electric shock each time they were placed inside.

Mice whose Tet1 was "knocked out" learned to associate the cage with the shock, just like the normal mice, but when the researchers put the mice back in the same cage without delivering the shock, the two groups behaved differently.

To the astonishment of scientists, mice with the Tet1 gene did not fear the cage, because their memory of being hurt had already been replaced by new information.

Follow this link:
Memory-Erasing Gene Discovered In Mice

Boston, MA (PRWEB) September 23, 2013

In a paper recently published in the prestigious journal Neuron, Harvard Medical School/Mass General Hospital Geneticist Dr. Rudy Tanzi, together with lead author, Dr. Jaehong Suh and their team, identified two rare mutations in the human gene called "ADAM10" that lead to the most common, late-onset variant of Alzheimer's. Tanzi's research suggests that the ADAM10 gene makes an enzyme called alpha-secretase, which cleaves the Amyloid Precursor Protein (APP) to prevent the formation of beta-amyloid, the toxic protein that triggers brain pathology in Alzheimer's disease.

This landmark genetic discovery by Tanzi, who is also Research Consortium Chair at Cure Alzheimer' Fund, further supports the widely-held "Amyloid Hypothesis" and suggests specific new therapeutic approaches to stopping Alzheimer's disease.

In their study, Tanzi and Suh first identified two new human gene mutations in ADAM10 and then inserted them into Alzheimer's mouse models to track their effects in the brain. Subsequently, the team was able to demonstrate how the mutant genes diminish alpha-secretase activity leading to increased levels of beta-amyloid, the main component of senile plaques in Alzheimers disease.

These findings are the first to document novel Alzheimer's gene mutations in animal models since the mutations in the original four Alzheimer's genes -- APP, PSEN1, PSEN2, and APOE -- were discovered in the 1990s.

Furthermore, the effects in mouse brains strongly suggest that diminished alpha-secretase activity owing to the ADAM10 gene mutations causes Alzheimer's and therefore supports ADAM10 as a promising therapeutic target for the treatment and prevention of the disease. "If we can find or develop a drug to safely increase alpha-secretase activity," said Tanzi, "that would decrease the accumulation of beta-amyloid plaques and slow down or even stop the onset of the disease."

Cure Alzheimers Fund President and CEO Tim Armour said, "These discoveries are validation of the aggressive gene-centric approach long supported by Cure Alzheimer's Fund. With this new data, we have two more important pieces filling out the large puzzle of how Alzheimer's disease develops in the human brain. It's that much closer to a complete picture, and brings us that much closer to a cure."

About Cure Alzheimers Fund

The Cure Alzheimers Fund is governed by a board of directors; administered by a small, full-time staff; and guided scientifically by a Research Consortium. Cure Alzheimer's Fund is a 501(c)(3) public charity. Cure Alzheimers Fund has supported 72 projects in 51 laboratories of leading Alzheimers researchers in the US and abroad.

Read more from the original source:
Alzheimer’s Disease: Landmark Gene Discoveries Open Up New Therapeutic Opportunities

Public release date: 23-Sep-2013 [ | E-mail | Share ]

Contact: Miranda Taylor tayl0551@umn.edu 612-626-2767 University of Minnesota Academic Health Center

MINNEAPOLIS/ST. PAUL (09/23/2013) -- New research from the University of Minnesota College of Veterinary Medicine (CVM) has uncovered the role gene ORMDL3 plays in the disease asthma. ORMDL3, a gene recently linked to asthma susceptibility, has now been linked to the body's ability to recruit inflammatory cells during an airway allergic reaction. Study findings appear today in the journal Nature Communications.

U of M researchers including Srirama Rao, Ph.D., (P. Sriramarao), CVM professor in the Department of Veterinary and Biomedical Sciences and associate dean for research, as well as professor in the U of M Medical School's Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, has identified a function of how ORMDL3 regulates the recruitment of inflammatory cells to airways, thus causing airway inflammation, in a mouse model.

Sung Gil Ha, Ph.D., a CVM post-doctoral fellow and the study's lead author, and colleagues have identified factors that up-regulate the ORMDL3 gene in specific white blood cells such as eosinophils during allergic asthma. Eosinophils are white blood cells intended to help protect the body from parasites; however, in the case of certain types of inflammation including exposure to allergens, instead of providing protection, they can cause tissue damage leading to asthma or other allergic disorders.

Not much is known about the function of ORMDL3 in asthma. By silencing or over-expressing ORMDL3 in eosinophils, the group has identified molecules regulated by the gene. These molecules enable eosinophils to congregate in airways where they cause allergic inflammation.

When turning the ORMDL3 gene off, researchers found lower levels of integrins expressed on the surface of eosinophils, meaning a decreased ability of eosinophils to migrate and cause inflammation in the airways.

"While exciting, our finding is just one piece of the puzzle," said Rao. "The more we understand about various asthma susceptibility genes including ORMDL3, the better positioned we will be to strategize new treatment options."

The discovery provides momentum for future understanding of the pathogenesis of asthma and role of genetics in inflammatory allergic reactions. This research is not only relevant for asthma but potentially other allergic disorders such as those of the GI tract and skin. The American Academy of Allergy, Asthma & Immunology estimates the number of asthma suffers internationally at 300 million with 250,000 annual deaths attributed to the disease.

Genetic disposition can influence the severity or susceptibility to an asthmatic reaction to allergens or environmental factors such as stress and cold.

Read more from the original source:
U of M research uncovers gene's contribution to asthma susceptibility

Sep. 23, 2013 New research from the University of Minnesota College of Veterinary Medicine (CVM) has uncovered the role gene ORMDL3 plays in the disease asthma. ORMDL3, a gene recently linked to asthma susceptibility, has now been linked to the body's ability to recruit inflammatory cells during an airway allergic reaction. Study findings appear today in the journal Nature Communications.

U of M researchers including Srirama Rao, Ph.D., (P. Sriramarao), CVM professor in the Department of Veterinary and Biomedical Sciences and associate dean for research, as well as professor in the U of M Medical School's Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, has identified a function of how ORMDL3 regulates the recruitment of inflammatory cells to airways, thus causing airway inflammation, in a mouse model.

Sung Gil Ha, Ph.D., a CVM post-doctoral fellow and the study's lead author, and colleagues have identified factors that up-regulate the ORMDL3 gene in specific white blood cells such as eosinophils during allergic asthma. Eosinophils are white blood cells intended to help protect the body from parasites; however, in the case of certain types of inflammation including exposure to allergens, instead of providing protection, they can cause tissue damage leading to asthma or other allergic disorders.

Not much is known about the function of ORMDL3 in asthma. By silencing or over-expressing ORMDL3 in eosinophils, the group has identified molecules regulated by the gene. These molecules enable eosinophils to congregate in airways where they cause allergic inflammation.

When turning the ORMDL3 gene off, researchers found lower levels of integrins expressed on the surface of eosinophils, meaning a decreased ability of eosinophils to migrate and cause inflammation in the airways.

"While exciting, our finding is just one piece of the puzzle," said Rao. "The more we understand about various asthma susceptibility genes including ORMDL3, the better positioned we will be to strategize new treatment options."

The discovery provides momentum for future understanding of the pathogenesis of asthma and role of genetics in inflammatory allergic reactions. This research is not only relevant for asthma but potentially other allergic disorders such as those of the GI tract and skin. The American Academy of Allergy, Asthma & Immunology estimates the number of asthma suffers internationally at 300 million with 250,000 annual deaths attributed to the disease.

Genetic disposition can influence the severity or susceptibility to an asthmatic reaction to allergens or environmental factors such as stress and cold.

The ORMDL3 gene studied by U of M researchers has been linked to asthma in various ethnic groups worldwide.

Follow this link:
Research uncovers gene's contribution to asthma susceptibility

Genetic Engineering by Dominique Bradley

By: dominique bradley

Read more here:
Genetic Engineering by Dominique Bradley - Video

Public release date: 23-Sep-2013 [ | E-mail | Share ]

Contact: Allison Snow Snow.1@osu.edu 614-292-3445 Ohio State University

COLUMBUS, Ohio Rice containing an overactive gene that makes it resistant to a common herbicide can pass that genetic trait to weedy rice, prompting powerful growth even without a weed-killer to trigger the modification benefit, new research shows.

Previously, scientists have found that when a genetically modified trait passes from a crop plant to a closely related weed, the weed gains the crop's engineered benefit resistance to pests, for example only in the presence of the offending insects.

This new study is a surprising example of gene flow from crops to weeds that makes weeds more vigorous even without an environmental trigger, researchers say.

The suspected reason: This modification method enhances a plant's own growth control mechanism, essentially making it grow faster an attractive trait in crops but a recipe for potential problems with weedy relatives that could out-compete the crop.

"Our next question is whether this method of enhancing plant growth could be developed for any crop. We want to know whether growers could get higher yields in the crop and then, if it happened to cross with a related weed, whether it might make the weed more prolific as well," said Allison Snow, professor of evolution, ecology and organismal biology at The Ohio State University and a lead author of the paper.

"It's unusual for any transgene to have such a positive effect on a wild relative and even more so for herbicide resistance," she said. "But we think we know why: It's probably because the pathway regulated by this gene is so important to the plant."

The work is the result of Snow's longtime collaboration with senior author Bao-Rong Lu, a professor at Fudan University in Shanghai. Their publication appears online in the journal New Phytologist.

The weed-killer glyphosate, sold under the brand name Roundup, kills plants by inhibiting a growth-related pathway activated by the epsps gene. Biotech companies have inserted mutated forms of a similar gene from microbes into crop plants, producing "Roundup Ready" corn and soybeans that remain undamaged by widespread herbicide application.

Read the original here:
Modifying rice crops to resist herbicide prompts weedy neighbors' growth spurt

St. Louis, MO (PRWEB) September 23, 2013

Appistry, Inc., a leading provider of high-performance computing and analytics solutions for next-generation medicine and the authorized distributor of select genetic analysis tools from the Broad Institute, today announced its chief scientific officer, Dr. Richard Mazzarella, will deliver a presentation titled Clinical Best Practices for Cancer Genetic Analysis Pipelines, at Cambridge HealthTech Institutes inaugural Clinical Genomics for Cancer Diagnostics Conference in Boston Sept. 23-24 at the Seaport Hotel. In his presentation, which will kick off the Data Interpretation conference track on Sept. 24, Mazzarella will illustrate how the use of de facto standard genetic analysis tools enables labs to commit more bioinformatics resources to more challenging and less well-understood pipeline development tasks.

Genetic analysis is a rapidly changing field, but certain tools are emerging as best practices because they have been used in a wide range of studies and in large-scale efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium, Mazzarella said. Running pipelines based on these validated tools conserves development effort for those analysis tasks that require truly innovative approaches and more extensive evaluation.

Appistry, a sponsor of the conference, will also exhibit its software solutions geared toward helping clinical labs take their next-generation sequencing (NGS) pipelines into production. As an exhibitor at booth number 7, Appistry will share with conference attendees the challenges of implementing NGS sequencing in clinical labs in the context of its computing environment, Ayrris. The technology applies computing capabilities developed for the analysis of big data in sectors such as finance and defense to the analysis of genetic data and the development of next-generation medicine.

The Clinical Genomics for Cancer Diagnostics Conference will examine novel diagnostic tools and techniques, evaluate their benefit to patient outcome, and focus on steps to implementation. The two-day event will gather leaders in cancer genomics, bioinformatics, clinical genomics, pharmacogenomics, diagnostics, internal medicine, molecular biology, and translational research.

Following the conference, Appistry will also host a webinar featuring the latest pipeline and tools for cancer genetic analysis from the Broad Institute. The one-hour webinar titled Which Mutations Matter: Analyzing and Annotating Cancer Genomes, will take place on Oct. 3, 2013 at 12 p.m. EDT. For more information and to register for the free event, please visit appistry.com/webinar.

About Appistry Appistry (http://www.appistry.com) orchestrates solutions to big data problems and since 2001, Appistrys fabric technology has empowered organizations and researchers to transform vast data into actionable intelligence. Appistry leverages its fabric computing technology to power Ayrris, a big-data environment that weaves together high performance computing and analytics to provide the throughput and scale required for diverse applicationsfrom discovering new medical therapies to delivering overnight packages, gaining clarity from financial transactions, or deciphering military satellite images. Appistry is the authorized distributor of the GATK and select genetic analysis tools from the Broad Institute for use in for-profit settings. For the latest Appistry news, visits us on Facebook, Twitter and LinkedIn.

More:
Appistry Chief Scientific Officer to Speak at Inaugural Conference on Delivering Genome-Enabled Diagnostics in the ...

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? Nightline Fix Beyond the Headline Local Popular Search Keyword News Search

See the article here:
Sequenom will review genetic analysis unit options

SEATTLE, WA--(Marketwired - Sep 23, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, today announced that Dr. Steven C. Quay, Chairman, President & CEO, will conduct a free webinar via The Money Show, titled, "How to Invest Ahead of Breast Cancer Awareness Month." The webinar will take place on Wednesday, September 25, from 4:30-5:30 pm Eastern Time. Investors interested in registering for this webinar should visit: http://www.moneyshow.com/video/Webinar/103/1A456567F8B24A07A44EBE518B571002/How-to-Invest-Ahead-of-Breast-Cancer-Awareness-Month/# and click on REGISTER FREE.

Dr. Quay stated, "October will be our first Breast Cancer Awareness Month as a public company. This free webinar will provide investors with an opportunity to learn about Atossa's unique business approach to the prevention of breast cancer through its patented medical devices and laboratory testing services, including the ForeCYTE Breast Health Test for breast cancer risk assessment."

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office.The test specimens are then analyzed at Atossa's laboratory, The National Reference Laboratory for Breast Health, Inc. (NRLBH), which can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight-year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes. For more information, please visit http://www.getforecyte.com.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, The NRLBH, patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information, on Atossa and the NRLBH, please visit http://www.atossagenetics.com and http://www.nrlbh.com. For further information on the ForeCYTE Breast Health Test, please visit http://www.getforecyte.com.

Forward-Looking Statements

View original post here:
Atossa Genetics to Conduct Free Webinar: How to Invest Ahead of Breast Cancer Awareness Month

(Reuters) - Alnylam Pharmaceuticals Inc said its experimental gene-based therapy reduced the level of a disease-causing protein, which leads to a rare organ-damaging hereditary disorder, in an early-stage trial.

The therapy was also found to be generally safe and well tolerated, Alnylam said in a statement.

The trial was testing Alnylam's subcutaneously delivered therapy for the treatment of an inherited, progressively debilitating and fatal disease caused by mutations in the transthyretin (TTR) gene.

The disease, called TTR-mediated amyloidosis or ATTR, causes abnormal proteins to accumulate in body organs and tissue.

Alnylam's therapy led to consistent and statistically significant reduction of TTR protein levels of up to 94 percent in the study.

The therapy is based on Alnylam's gene silencing technology that works by "switching off" certain disease-causing genes and is widely believed to hold immense potential for treating diseases ranging from cancer to HIV.

The company now plans to start a pilot mid-stage trial by the end of this year, and assuming positive results, a late-stage study by the end of 2014.

Alnylam shares closed at $57.23 on Friday on the Nasdaq.

(Reporting by Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal)

Go here to read the rest:
Alnylam’s ATTR gene therapy effective in early-stage trial

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? Nightline Fix Beyond the Headline Local Popular Search Keyword News Search

Read more here:
Alnylam's gene therapy shows strong efficacy data

NorthStar Genetics, Early Maturing Soybean Varieties - Part 5
Pitura Seeds takes a look at some early maturing soybean varieties.

By: Pitura Seeds

Read the rest here:
NorthStar Genetics, Early Maturing Soybean Varieties - Part 5 - Video

Health Chat: The Genetics of Breast Cancer
Florida Hospital Celebration Health Breast Surgeon, Dr. Olga Ivanhov, discusses the genetics of Breast Cancer. For more information call 407-303-4760 or visi...

By: floridahospital

More here:
Health Chat: The Genetics of Breast Cancer - Video

Featured Article Academic Journal Main Category: Neurology / Neuroscience Also Included In: Psychology / Psychiatry Article Date: 21 Sep 2013 - 0:00 PDT

Current ratings for: Gene that triggers 'memory extinction' discovered

5 (3 votes)

4.92 (13 votes)

Many of us are the bearers of "bad" memories that, to this day, continue to affect our lives. Now, scientists say they have discovered a gene essential for "memory extinction," the process by which our brain replaces older memories with new experiences.

Researchers from the Massachusetts Institute of Technology (MIT) say the discovery could help people suffering from post-traumatic stress disorder (PTSD) by replacing "fearful" memories with more positive associations.

The gene, Tet1, has been found to play a critical role in memory extinction by controlling a small group of other genes that are necessary for the process.

For the study, published in the journal Neuron, the research team experimented on mice who had the Tet1 gene "knocked out," as well as on mice who had normal levels of the gene.

In order to measure the mice's ability to abolish memories, the mice were "conditioned" to fear a certain cage in which they received a small electric shock. Once the memory of the "cage shock" was formed, the mice were placed into the cage, but the researchers did not give them the shock.

The researchers found that after a period of time, mice with normal Tet1 levels appeared to lose their fear of the cage, indicating that new memories replaced the old ones.

Excerpt from:
Gene that triggers 'memory extinction' discovered

PEMBROKE Genetic engineering, climate change and history were all on the menu as an environmental activist and former two-time vice presidential candidate shared what she called the covenant American Indians have with their food.

About 60 students and faculty from The University of North Carolina at Pembroke and local residents came to The Regional Center at COMtech to hear Winona LaDukes presentation on ecological sustainability and self-sufficiency on Thursday. The presentation was part of UNCPs Native American Speakers Series and the 2013 Conference of American Indian Women of Proud Nations, which began Wednesday and concludes today.

LaDuke, an Anishinaabe Indian, said food is a lifeline to Americans Indians culture and heritage, saying the Anishinaabe tribe was told to go to where food grows on the water, which led them to the rice paddies of Minnesota. She highlighted her point in a video showing Anishinaabe men harvesting wild rice during an annual ritual on their reservation.

Its not just a commodity, LaDuke said. Its a covenant.

To protect that bond, LaDuke said she and her family waged an eight-year battle against the federal government to stop the genetic engineering of indigenous wild rice.

If genetic engineering is the answer, what was the question? she said.

LaDuke said climate change and the use of fossil fuels are causing ecological ruin around the world, especially with the way fuels are extracted from the Earth.

Carbon belongs in the soil, not in the air, she said. When you go to extremes, you do things like frack and blow the tops off of 500 mountains because youre desperate.

LaDuke showed photos of houses in an Alaskan village crumbling because the foundation underneath is melting, which she said is evidence that geography is changing.

Anyone who thinks climate change isnt happening is highly delusional, she said.

See the original post:
Indian activist says answers to Earth’s woes found in dirt -

Irvine, CA (PRWEB) September 20, 2013

Proove Biosciences, Inc., the leading personalized pain medicine laboratory, is excited to announce that they will be attending and exhibiting at the California Society of Interventional Pain Physicians 4th Annual Meeting this weekend at the Terranea Resort in Rancho Palos Verdes, California. The event will be held from September 20th to September 22nd.

CASIPP is a growing advocacy society working for interventional pain management physicians and their staff within the state of California. The organizations mission is to promote the development and practice of safe, high quality, cost-effective interventional pain medicine techniques for the diagnosis and treatment of pain and related disorders, and ensure patient access to these interventions.

We are proud to support Dr. Ray d'Amours, the President and Executive Director of CASIPP in this important conference, explains Proove CEO and founder, Brian Meshkin. Proove is a research-driven company committed to realizing the potential of personalized pain medicine. We are proud to stand with Dr. dAmours and his colleagues at the forefront of pain medicine genetics. We continue to be the only company to present clinical research on the genetics of pain medicine at scientific meetings throughout the year including, PAINWeek, the American Pain Society, American Society of Addiction Medicine, and other major scientific meetings on pain management.

Proove Biosciences will be exhibiting at CASIPP and sharing information on its proprietary genetic testing services, including the Proove Narcotic Risk Genetics test that helps physicians identify genetic predisposition to misuse of prescription narcotic pain medications and the Proove Drug Metabolism Genetics test that helps physicians understand the genetic predisposition to drug metabolism.

The meeting will consist of a variety of lectures, workshops, and speakers that cover topics ranging from pain management and therapy optimization, to the current political landscape of California pain management and treatment. Additionally, there will be opportunities for Continued Medical Education (CME) credit.

About Proove Biosciences Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

See original here:
Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting ...

Let #39;s Play The Sims 3 - Perfect Genetics Challenge - Episode 28
My Sims 3 Page: http://mypage.thesims3.com/mypage/Llandros2012 My Blog: http://Llandros09.blogspot.com My Facebook: https://www.facebook.com/Llandros09?ref=t...

By: Llandros09

Read the original here:
Let's Play The Sims 3 - Perfect Genetics Challenge - Episode 28 - Video

2014 Genetics
Meds for 2014.

By: CultivatedCaregivers

Read the original:
2014 Genetics - Video

LOS ANGELES, Sept. 20, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has entered into definitive agreements with institutional investors for the sale of 932,805 shares of its common stock in a registered direct offering at $2.05 per share, the closing price on September 19, 2013. Gross proceeds of the offering, before deducting the placement agent fee and offering expenses, are expected to be approximately $1.9 million.

The offering is expected to close on or about September 25, 2013, subject to the satisfaction of customary closing conditions. Response Genetics intends to use the net proceeds from the offering primarily to expedite the integration of the recently acquired proprietary FDA-cleared and Medicare-reimbursed Tissue of Origin test for difficult to diagnose solid tumors and all associated assets, as more fully described in the Company's press release dated August 26, 2013 and related Form 8-K.

"This additional capital is primarily intended to facilitate a focused and expedited integration of this portfolio enhancing product," said Thomas Bologna, Chairman and Chief Executive Officer of Response Genetics. "In conjunction with this effort, we are excited to begin immediate construction of additional laboratory space in our Los Angeles facility. We intend to offer this proprietary Tissue of Origin test, Response Dx: TOOTM, to new and existing customers starting in the first quarter of 2014."

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), acted as the placement agent for this offering.

The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the registration statement, final base prospectus and accompanying prospectus relating to the offering may be obtained from the Securities and Exchange Commission's website at http://www.sec.gov or from Ladenburg Thalmann & Co. Inc., 520 Madison Avenue, 9th Floor, New York, New York 10022.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Visit link:
Response Genetics, Inc. Announces $1.9 Million Registered Direct Offering

RUTHERFORD, N.J., Sept. 20, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (CGIX) ("CGIX" or the "Company"), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, was featured in an article in USA TODAY titled "Targeted therapy and companion diagnostics go hand and hand." The article is available online at:

http://us.mediaplanet.com/future-of-cancer-care/hand-in-hand-how-targeted-therapy-and-companion-diagnostics-are-changing-outcomes-for-cancer-patients

Additionally, the September 20 print edition of USA TODAY features a panel discussion with Dr. Raju Chaganti, founder and chairman of CGIX. In the panel discussion, Dr. Chaganti and other leading oncology experts share insights about advancements that are impacting the future of cancer care.

The panel discussion includes information on the newest diagnostic and treatment options available to patients, how changes in technology have impacted cancer care, forecasts for new technology advancements, and other topics driving innovation in the industry.

"The Future of Cancer Care" insert will be available in print editions of USA TODAY on September 20 in the following markets: New York City, Philadelphia, Washington D.C., Baltimore, Cincinnati and Chicago. USA TODAY online sites have 26.3 million unique visitors per month. An online version of the insert is available at:

http://us.mediaplanet.com/future-of-cancer-care/

A PDF of the insert as featured in USA TODAY is available at:

http://doc.mediaplanet.com/all_projects/12832.pdf

CGIX is a sponsor of "The Future of Cancer Care" insert.

About Cancer Genetics:

View original post here:
Cancer Genetics, Inc. Featured in USA TODAY Article

ATLANTA, GA--(Marketwired - Sep 20, 2013) - Atossa Genetics Inc. (NASDAQ: ATOS) is proud to announce its sponsorship of The Third Annual Power of Pink luncheon, fashion show and silent auction. The event will take place at the Country Club of the South in Johns Creek, Georgia, on Friday, September 20, 2013.

This year, North Fulton Hospital, through its Check-Up for Chicks program, is again taking a stand in the fight against breast cancer with the Power of Pink. More than 300 of North Atlanta's most passionate supporters of breast health and breast cancer research will be in attendance.

"We are proud to sponsor this important annual event in the quest to raise breast cancer awareness and fight this devastating disease," stated Chris Destro, VP of Sales & Marketing at Atossa. In addition to sponsoring events and supporting efforts like Power of Pink, we are contributing to the fight against breast cancer with the national rollout of our ForeCYTE Breast Health Test. The ForeCYTE test is a revolutionary new product that detects reversible precancerous conditions in the breastapproximately 8years before they become cancer, enabling physicians and their patients to obtain valuable, science-based information to manage their breast health."

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office.The test can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes.For more information, please visit getforecyte.com.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information, on Atossa and the NRLBH, please visit http://www.atossagenetics.com and http://www.nrlbh.com. For further information on the ForeCYTE Breast Health Test, please visit http://www.getforecyte.com.

Link:
Atossa Genetics to Sponsor Power of Pink Event in Johns Creek, Georgia

SYDNEYand AUCKLAND, New Zealand, Sept. 19, 2013 /PRNewswire/ --Living Cell Technologies Limited (LCT) today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL(R) a potential treatment for Parkinson's disease.

The pioneering brain surgery was conducted at Auckland City Hospital and the patient has recovered well so far. An MRI scan taken the day after the surgery indicated that the NTCELL capsules have been implanted at their intended target. The patient and family have requested privacy and no contact with the media.

The Phase I clinical trial is an open label investigation of the safety and clinical effect of NTCELL in four people who have been diagnosed with Parkinson's disease for at least four years. The first patient will now be monitored for two months to confirm no serious adverse safety events. At that time, the independent data safety monitoring board (DSMB) will consider the safety data and advise if the implants for the remaining three patients can proceed.

The trial Principal Investigator is Dr Barry Snow (MBChB, FRACP, FRCPC), an internationally recognised clinician and researcher in Parkinson's disease who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board. "The team are pleased with how well the patient tolerated the procedure itself," says Dr Snow. "The surgery is relatively straightforward in neurosurgery terms, and we have taken full advantage of well-established techniques, which lowers the clinical risk. The patient will now be monitored closely by the team over the next two months."

Dr Andrea Grant, CEO and Managing Director of LCT says: "This is a significant milestone and a world first. It has taken a great deal of hard work, clinical and scientific endeavour to get to this and so of course we are excited. The purpose of this "first-in-man" study is to demonstrate the treatment is safe. Provided this trial is succesful, future trials will further assess the extent of clinical benefit that patients might gain."

In the clinical trial, NTCELL is injected under guidance by neuroimaging into the affected area of the human brain where substantial death of neurons and other cells has occurred. The cell therapy is comprised of choroid plexus cells, which are naturally occurring 'support' cells for the brain. LCT's propriety technology IMMUPEL(R) coats the implanted cells to protect them from attack by the patient's immune system.

The scientific basis for the Phase I clinical trial in humans was established from the published preclinical trial of NTCELL(R) in a non-human primate model of Parkinson's disease. The preclinical results indicate that NTCELL can protect and regenerate brain tissue that would otherwise be lost, potentially delaying or even preventing the effects of Parkinson's disease.

"Unlike current therapy options for Parkinson's disease, NTCELL may be neuroprotective and offers people living with the disease the hope of being able to halt disease progression and restore quality of life," says Dr Grant.

LCT and Otsuka Pharmaceutical Factory (OPF) are co-developing NTCELL as a treatment for Parkinson's disease. Under the agreement, LCT has already received an A$3m cash payment and OPF is funding all of the research and development costs associated with the Phase I clinical trial, estimated at AU$2.1m. In addition, LCT will receive a second cash payment of AU$2m provided the DSMB authorise the remaining three implants later in the year.

For further information: http://www.lctglobal.com

Read more:
'First-in-man' Implant of Regenerative Cell Therapy in Parkinson's Disease